Cargando…
Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation
OBJECTIVES: Graves’ disease is secondary to the presence of anti-thyrotropin receptor antibodies (TRAb), which stimulate thyroid hormones. TRab determination is crucial for etiological diagnosis. The objectives of this study were (i) to compare two methods for determining TRab by chemoluminiscence v...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197409/ https://www.ncbi.nlm.nih.gov/pubmed/37363331 http://dx.doi.org/10.1515/almed-2021-0015 |
_version_ | 1785044545989246976 |
---|---|
author | Silvestre, Ramona A. Almería Lafuente, Alejandro Jiménez-Mendiguchía, Lucía García-Cano, Ana Romero López, Rubén García-Izquierdo, Belén Pardo de Santayana, Cristina Iglesias, Pedro Diez, Juan J. Arribas Gómez, Ignacio Bernabeu-Andreu, Francisco A. |
author_facet | Silvestre, Ramona A. Almería Lafuente, Alejandro Jiménez-Mendiguchía, Lucía García-Cano, Ana Romero López, Rubén García-Izquierdo, Belén Pardo de Santayana, Cristina Iglesias, Pedro Diez, Juan J. Arribas Gómez, Ignacio Bernabeu-Andreu, Francisco A. |
author_sort | Silvestre, Ramona A. |
collection | PubMed |
description | OBJECTIVES: Graves’ disease is secondary to the presence of anti-thyrotropin receptor antibodies (TRAb), which stimulate thyroid hormones. TRab determination is crucial for etiological diagnosis. The objectives of this study were (i) to compare two methods for determining TRab by chemoluminiscence vs. standard TRACE-immunofluorescence; (ii) to determine the diagnostic validity of the three methods. METHODS: A retrospective study in 194 patients with a TRAb determination request. TRAb were determined by immunofluorescence (Kryptor, ThermoFisher) and chemiluminescence (Immulite, Siemens and Maglumi, Snibe). Clinical validation: medical records were reviewed and categorized according to thyroid function. Statistical analysis: Differences in quantitative variables were assessed by intraclass correlation coefficient, Bland–Altman plot, and mean differences (mD). Qualitative variables were dichotomized by cut-off points; Kappa coefficient was calculated. Correlations were evaluated by Pearson’s coefficient and Passing-Bablok regression analysis. The diagnostic validity of the three methods was investigated. RESULTS: Kryptor-Immulite: mD: 1.2 (95%CI: −16 to >18). Passing-Bablok: Constant error (95%CI: −0.8349 to −0.5987). Proportional error (95%CI: 0.7862–1.0387). ICC: 0.86 (95%CI: 0.82–0.89). Kappa coefficient: 0.68 (95%CI 0.59–0.78). Kryptor-Maglumi: mD: −0.3 (95%CI: −12 to >12). Passing-Bablok: Constant error (95%CI: −0.7701 to >0.1621. Proportional error (95%CI: 0.8571 to 1.3179. ICC: 0.93 (95%CI: 0.89–0.97). Kappa coefficient: 0.53 (95%CI: 0.32–0.74). Diagnosis of Graves’ disease was confirmed in 113 patients (Kryptorf showed better specificity and positive predictive value, whereas Immulite demonstrated better sensitivity and negative predictive value). CONCLUSIONS: The three methods have a good diagnostic performance for Graves’ disease, with superimposable results on Bland–Altman plot. Interchangeability was not confirmed on the regression and agreement analysis, with the presence of biases. |
format | Online Article Text |
id | pubmed-10197409 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | De Gruyter |
record_format | MEDLINE/PubMed |
spelling | pubmed-101974092023-06-23 Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation Silvestre, Ramona A. Almería Lafuente, Alejandro Jiménez-Mendiguchía, Lucía García-Cano, Ana Romero López, Rubén García-Izquierdo, Belén Pardo de Santayana, Cristina Iglesias, Pedro Diez, Juan J. Arribas Gómez, Ignacio Bernabeu-Andreu, Francisco A. Adv Lab Med Article OBJECTIVES: Graves’ disease is secondary to the presence of anti-thyrotropin receptor antibodies (TRAb), which stimulate thyroid hormones. TRab determination is crucial for etiological diagnosis. The objectives of this study were (i) to compare two methods for determining TRab by chemoluminiscence vs. standard TRACE-immunofluorescence; (ii) to determine the diagnostic validity of the three methods. METHODS: A retrospective study in 194 patients with a TRAb determination request. TRAb were determined by immunofluorescence (Kryptor, ThermoFisher) and chemiluminescence (Immulite, Siemens and Maglumi, Snibe). Clinical validation: medical records were reviewed and categorized according to thyroid function. Statistical analysis: Differences in quantitative variables were assessed by intraclass correlation coefficient, Bland–Altman plot, and mean differences (mD). Qualitative variables were dichotomized by cut-off points; Kappa coefficient was calculated. Correlations were evaluated by Pearson’s coefficient and Passing-Bablok regression analysis. The diagnostic validity of the three methods was investigated. RESULTS: Kryptor-Immulite: mD: 1.2 (95%CI: −16 to >18). Passing-Bablok: Constant error (95%CI: −0.8349 to −0.5987). Proportional error (95%CI: 0.7862–1.0387). ICC: 0.86 (95%CI: 0.82–0.89). Kappa coefficient: 0.68 (95%CI 0.59–0.78). Kryptor-Maglumi: mD: −0.3 (95%CI: −12 to >12). Passing-Bablok: Constant error (95%CI: −0.7701 to >0.1621. Proportional error (95%CI: 0.8571 to 1.3179. ICC: 0.93 (95%CI: 0.89–0.97). Kappa coefficient: 0.53 (95%CI: 0.32–0.74). Diagnosis of Graves’ disease was confirmed in 113 patients (Kryptorf showed better specificity and positive predictive value, whereas Immulite demonstrated better sensitivity and negative predictive value). CONCLUSIONS: The three methods have a good diagnostic performance for Graves’ disease, with superimposable results on Bland–Altman plot. Interchangeability was not confirmed on the regression and agreement analysis, with the presence of biases. De Gruyter 2021-03-02 /pmc/articles/PMC10197409/ /pubmed/37363331 http://dx.doi.org/10.1515/almed-2021-0015 Text en © 2021 Ramona A. Silvestre et al., published by De Gruyter, Berlin/Boston https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. |
spellingShingle | Article Silvestre, Ramona A. Almería Lafuente, Alejandro Jiménez-Mendiguchía, Lucía García-Cano, Ana Romero López, Rubén García-Izquierdo, Belén Pardo de Santayana, Cristina Iglesias, Pedro Diez, Juan J. Arribas Gómez, Ignacio Bernabeu-Andreu, Francisco A. Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation |
title | Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation |
title_full | Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation |
title_fullStr | Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation |
title_full_unstemmed | Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation |
title_short | Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation |
title_sort | comparison of three methods for determining anti-thyrotropin receptor antibodies (trab) for diagnosis of graves’ disease: a clinical validation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197409/ https://www.ncbi.nlm.nih.gov/pubmed/37363331 http://dx.doi.org/10.1515/almed-2021-0015 |
work_keys_str_mv | AT silvestreramonaa comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation AT almerialafuentealejandro comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation AT jimenezmendiguchialucia comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation AT garciacanoana comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation AT romerolopezruben comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation AT garciaizquierdobelen comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation AT pardodesantayanacristina comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation AT iglesiaspedro comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation AT diezjuanj comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation AT arribasgomezignacio comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation AT bernabeuandreufranciscoa comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation |